Oracle ended its fiscal third quarter with $553 billion in remaining purchase obligations -- up 325% year over year.

The 40-card oracle deck was born out of the relationship the illustrator and writer formed while on a trip to Egypt. We took ...

While Oracle has traditionally been viewed as a legacy database provider, its aggressive pivot toward Oracle Cloud ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Several global giants listed as victims of the Oracle EBS hack have remained mum on the impact of the cybersecurity incident.

Oracle's OCI revenue is growing 66% YOY, outpacing AWS and Azure. Oracle is selling profitable business units and accumulating tens of billions in debt to fund the data center expansion needed to ...

The chip cycle is moving so fast that even the biggest infrastructure deals can’t keep up.” That line from CNBC’s Deirdre Bosa captures the core tension now rattling AI infrastructure investors.

Is Oracle Corp.’s reported $300 billion infrastructure deal with OpenAI a sign of robust artificial-intelligence spending for years to come — or an indication that AI players have gotten ahead of ...

Oracle Corp. and OpenAI have scrapped plans to expand a flagship artificial intelligence data center in Texas after negotiations dragged over financing and OpenAI’s changing needs. The collapsed talks ...

Shares in Oracle, one of the world’s largest computing infrastructure companies, fell by 29.4% in the month to 13 November, as concerns over the feasibility of artificial intelligence (AI) spending ...

Dozens of hospitals have had their patient data compromised by a 2025 breach of Oracle Health’s legacy Cerner systems. Health systems continue to alert patients of the hack that occurred as early as ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...